No evidence of increased risk of acquired rifampin resistance

摘要

We read with interest the recent CMAJ commentary by Batt and Khan1 about our recent publications of trials comparing 4 months of rifampin with 9 months of isoniazid in adults2 and children for latent tuberculosis (TB) infection.3 In those 2 trials, and in an earlier trial involving adults,4 we have shown that 4 months of rifampin is consistently significantly superior to 9 months of isoniazid for completion and safety in adults and is very safe and well tolerated in children for treatment of latent TB. In both populations, the efficacy of 4 months of rifampin was noninferior to that of 9 months of isoniazid.2,3 In summary, 4 months of rifampin is shorter, safer, better-completed and as effective as 9 months of isoniazid. Seems like an easy choice for patients and providers.